Phase II Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma with Tumor Mutation Profiling

Phase II Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma with Tumor Mutation Profiling

Background: The mammalian target of rapamycin (mTOR) pathway is upregulated in nearly half of hepatocellular carcinoma (HCC) tumors and is associated with poor prognosis. In preclinical models of HCC, the combination of mTOR pathway inhibition with the multikinase inhibitor sorafenib improves treatm...

Full description

Bibliographic Details
Main Authors: Robin K. Kelley, Nancy M. Joseph, Halla S. Nimeiri, Jimmy Hwang, Laura M. Kulik, Zoe Ngo, Spencer C. Behr, Courtney Onodera, Karen Zhang, Andrea G. Bocobo, Al B. Benson, Alan P. Venook, John D. Gordan
Format: Article
Language:English
Published: Karger Publishers 2021-09-01
Series:Liver Cancer
Subjects:
sorafenib
temsirolimus
hepatocellular carcinoma
mammalian target of rapamycin
next-generation sequencing
Online Access:https://www.karger.com/Article/FullText/518297

Internet

https://www.karger.com/Article/FullText/518297

Similar Items